ArticleOncology and therapy2025

Real-World Use and Immunotherapy Rechallenge Outcomes with Nivolumab in Advanced Non-small Cell Lung Cancer in France: Interim Results of the LIST Study.

Benoît Godbert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.